Jan Wald
Jan Wald
bent
It underscores why they were so bent on doing the Guidant deal.
They were being nickel-and-dimed by J&J. They had to get out of that loop.
johnson stronger threat
The combination of Guidant and Johnson & Johnson is a stronger threat to Medtronic,
actions louder speak
This is one of those times when actions speak louder than words.
beginning fourth looked looking quarter
The end of the fourth quarter looked better than the beginning, and 2006 is looking OK.
boston less time worse
The less time they give Boston Scientific, the worse it is for Boston Scientific. They have less time to react.
amazing events turn
I think it's an amazing turn of events.
attractive certainly definitely
I think they (St. Jude) definitely look like they are in play. They certainly would be an attractive candidate.
easily
I think they easily could go up to $76 without a lot of damage.
ask boston hold holding johnson paper rather whether
If you're a Guidant shareholder, you have to ask yourself whether you'd rather hold Boston paper or Johnson & Johnson paper. I would rather hold Boston, because I'm holding Guidant for growth.
bid learnt sensitive
It's still a possibility. But the valuation is high, and one thing we learnt from the J&J bid for Guidant is they are very sensitive to valuation.
bid learned sensitive
It's still a possibility. But the valuation is high, and one thing we learned from the J&J bid for Guidant is they are very sensitive to valuation.
chance good sure
I don't think it's a sure thing by any stretch, but I think they have a good chance of making it.